🔴 Arcturus Therapeutics is trading 5.6% down today amid possible reassessment of prior ARCT-810 data

Arcturus Therapeutics is trading at $13.34, down 5.56%, with no new company-specific announcement identified to explain the September 25 decline.

• Investors may be reassessing prior ARCT-810 interim data and the LUNAR 2.0 transition announced September 23–24.
• Broader indexes are modestly higher, offering limited support for attributing the decline to market weakness.